The "July phenomenon": is trauma the exception?
The July phenomenon does not exist at this Level I trauma center with in-hospital attending supervision.
This study revealed that SLC22A11 and ABCC1 may be important to identify those patients who will not benefit from MTX treatment, highlighting the relevance in translating these results to clinical practice. However, further validation by independent studies is needed to develop the field of personalized medicine to predict clinical response to MTX treatment.